Chosa Oncology Valuation

Q: What is the Fair Price of W5L when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

W5L (€0.08) is trading below our estimate of [[fair value]] (€110.78)

Is W5L undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of W5L when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: W5L (€0.08) is trading below our estimate of fair value (€110.78)

Significantly Below Fair Value: W5L is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for W5L?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for W5L. This is calculated by dividing W5L's market cap by their current preferred multiple.
What is W5L's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 37.60m

W5L key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	3.3x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does W5L's PB Ratio compare to its peers?

The above table shows the PB ratio for W5L vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	11.7x
CNW co.don	1x	n/a	€6.5m
T5O bioXXmed	1.2x	n/a	€585.7k
MDG1 Medigene	1.4x	-4.1%	€27.4m
VSC 4SC	43.1x	n/a	€47.2m
W5L Chosa Oncology	n/a	n/a	€37.6m

Price-To-Book vs Peers: Insufficient data to calculate W5L's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Earnings Ratio vs Industry

How does W5L's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.7%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.7%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: Insufficient data to calculate W5L's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is W5L's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

W5L PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	n/a
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate W5L's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.